Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A 29-residue synthetic peptide corresponding to the N-terminal fragment of a 44-residue hypothalamic peptide, carrying four stabilizing residue substitutions and a C-terminal amide.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (tetrasubstituted, 29 residues)
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Amino acids
29
Sequence
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Modification
Tetrasubstituted GRF(1-29) (D-Ala2, Gln8, Ala15, Leu27); C-terminal amide. The substitutions are positioned to resist DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Unlike the DAC variant, it lacks the C-terminal albumin-binding maleimidopropionyl group.
A 29-residue synthetic peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide, studied structurally in the context of class B1 G-protein-coupled receptor complexes. Four substitutions relative to the native fragment — D-Ala2, Gln8, Ala15, and Leu27 — confer greater enzymatic and chemical stability against DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Because it lacks the DAC variant's albumin-binding group, it is short-circulating rather than long-circulating.
Lyophilized
20°C
lyophilized peptide stored desiccated and protected from light.
Aliquot to avoid repeated freeze-thaw; protect from light and moisture. Storage conventions reflect supplier guidance for lyophilized peptides of this class.
Reviews
Halmos G, et al. (2023). Vitamins and Hormones
Campbell RM, Bongers J, Felix AM. (1995). Biopolymers
Schally AV, et al. (2019). Endocrinology
Clinical
Sackmann-Sala L, et al. (2009). Growth Horm IGF Res
Teichman SL, et al. (2006). J Clin Endocrinol Metab
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
ClinicalTrials.gov registry. ClinicalTrials.gov
Chen RG, et al. (1993). Acta Paediatr Suppl
Neyzi O, et al. (1993). Acta Paediatr Suppl
Primary research
Zhou F, et al. (2020). Nat Commun
Cai R, Schally AV, et al. (2014). Peptides
Alba M, et al. (2006). Am J Physiol Endocrinol Metab
Jetté L, et al. (2005). Endocrinology
Dubreuil P, et al. (2001). Growth Horm IGF Res
Izdebski J, et al. (1995). Proc Natl Acad Sci USA
Bongers J, et al. (1992). Int J Pept Protein Res
Friedman AR, et al. (1991). Int J Pept Protein Res
Frohman LA, et al. (1989). J Clin Invest
Lance VA, et al. (1984). Biochem Biophys Res Commun
Stevenson CL, et al.. PubMed
Cui T, et al. (2018). Oncotarget
Also known as: Modified GRF (1-29), Mod GRF (1-29), Tetrasubstituted GRF (1-29), CJC-1295 without DAC
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| CJC-1295 No DACThis page | Synthetic peptide (tetrasubstituted, 29 residues) | ~3,368 g/mol | 863288-34-0 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods